Stanford

Judith Shizuru

Professor of Medicine (Blood and Marrow Transplantation) and of Pediatrics (Stem Cell Transplantation)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICES

- **Stanford Cancer Center**

  875 Blake Wilbur Dr Clinic F

  MC 5826

  Stanford, CA 94305

  Tel (650) 723-0822 **Fax** (650) 498-6159

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

  Sara Clark - Administrative Associate

  Email sara.clark@stanford.edu

  Tel 650-725-4959

Bio

BIO

I am a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program and the Institute of Stem Cell Biology and Regenerative Medicine. I have attended on the BMT clinical service since 1997, and I oversee a research laboratory. My current clinical efforts and basic research focus on improving the safety and efficacy of hematopoietic cell transplantation (HCT) which is the most widely practiced and powerful form of cellular therapy. To achieve this goal we address two fundamental issues of HCT – the preparation of the recipient to accept a transplanted hematopoietic graft, and the impact of the graft cellular content on the success of the therapy. We have applied our expertise to develop novel ways to achieve engraftment of blood forming stem cells with the goal to replace chemotherapy and radiation. We have also developed the tools and methods that will allow us to transplant grafts of pure blood forming stem cells with the goal to eliminate potentially harmful passenger cells contained in a blood stem cell graft.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Blood and Marrow Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Professor, Medicine - Blood & Marrow Transplantation
- Professor, Pediatrics - Stem Cell Transplantation
- Member, Bio-X
- Member, Cardiovascular Institute
- Member, Institute for Stem Cell Biology and Regenerative Medicine
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Member, Stanford Diabetes Research Center, (2018- present)

HONORS AND AWARDS

- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1986-1988)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1989-1991)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1991-1993)
- Excellence in Research in the Field of Hematopoiesis, Cheryl Whitlock Award (1996)
- Career Award in the Biomedical Sciences, Burroughs Wellcome Fund (1996-2000)
- Junior Faculty Scholars Award, Howard Hughes Medical Institute (1996-2000)
- Scholar Award, Amy Strelzer Manasevit (2001)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Medical Center (1997) CA
- Residency: UCSF Medical Center (1994) CA
- Internship: UCSF Medical Center (1993) CA
- Medical Education: Stanford University School of Medicine (1992) CA

LINKS

- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The research interests are to understand the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow (BM) cells and to understand the way in which BM grafts modify immune responses. This research complements our interest in clinical BM transplantation and aspects of these studies are aimed at solving some of the major problems of BM transplantation which include graft-vs-host disease and BM engraftment failure. Conventional BM transplantation involves the transfer of heterogeneous populations of cells composed of rare hematopoietic stem cells (HSCs) and differentiated blood cell types. To study these issues our approach has been to transplant phenotypically purified cells under defined conditions. The specific projects in my laboratory include:

1) Identification of the cells and molecules responsible for resistance to engraftment of purified allogeneic HSCs. We and others have shown that cells with NK determinants constitute a significant barrier to allogeneic HSC engraftment, and that transplanted whole BM contains a population that facilitates engraftment. In these experiments our approach to identify the cell population(s) and mechanism by which HSC engraftment is resisted is to use recipient mice from strains that lack defined immune functions. We are studying the cells in BM and spleen that are bound and/or depleted by a-ASGMI, and in this way identify the candidate barrier populations.

2) Use of transplants of purified HSCs to induce tolerance to allo- and autoantigens, and study of the mechanisms by which such tolerance is induced. We continue to develop preclinical models for organ tolerance induction and treatment of autoimmune disease by using cell specific therapy. One goal is to decrease the morbidity of the recipient preparative regimen and to determine the lowest level of chimerism needed to induce immune tolerance. We propose to test donor/host strain combinations most relevant to human disease, including minor mismatched and haploidentical grafts.

3) Identification of the cells and molecules that confer graft vs leukemia/lymphoma (GVL) effects. We have developed a model of B cell lymphoma relapse after HSC transplant. To date our studies show that while purified allogeneic HSCs have no GVL activity, a population of BM cells that express CD3 and CD8 have significant GVL activity, and do not cause GVHD at the cell doses administered.

CLINICAL TRIALS

- Bone Marrow Grafting for Leukemia and Lymphoma, Recruiting
- Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs., Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Recruiting
- Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL, Not Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102), Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML), Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801), Not Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- Haploid Allogeneic Transplant Using the CliniMACS System, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma, Not Recruiting
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT), Not Recruiting
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma, Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201), Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG, Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies, Not Recruiting
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant, Not Recruiting

- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease, Not Recruiting
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402), Not Recruiting
- Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors, Not Recruiting
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702), Not Recruiting
- Targeted Therapy of Bronchiolitis Obliterans Syndrome, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/ Peripheral Blood Progenitor Cell (PBPC) Transplantation, Not Recruiting
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Andriyana Bankova

Doctoral Dissertation Advisor (AC)

Brenda Velasco

Postdoctoral Research Mentor

Andriyana Bankova

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Immunology (Phd Program)
- Stem Cell Biology and Regenerative Medicine (Phd Program)

Publications

PUBLICATIONS

- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*

  Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al

  2015; 50 (10): 1286-1292

- **Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.** *Clinical cancer research*

  Filatenkov, A., Baker, J., Mueller, A. M., Kenkel, J., Ahn, G., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., Shizuru, J. A., Negrin, R. N., Engleman, et al

  2015; 21 (16): 3727-3739

- **Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation.** *American journal of transplantation*

  Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., Dejbakhsh-Jones, S., Jensen, K., Shori, A., Strober, J. A., Lavori, P., Turnbull, B. B., Engleman, E. G., Strober, et al

  2015; 15 (3): 695-704

- **A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency** *PEDIATRIC TRANSPLANTATION*

  Dvorak, C. C., Horn, B. N., Puck, J. M., Czechowicz, A., Shizuru, J. A., Ko, R. M., Cowan, M. J.

  2014; 18 (6): 602-608

- **Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.** *Radiation research*
  Filatenkov, A., Baker, J., Müller, A. M., Ahn, G., Kohrt, H., Dutt, S., Jensen, K., Dejbakhsh-Jones, S., Negrin, R. S., Shizuru, J. A., Engleman, E. G., Strober, S.
  2014; 182 (2): 163-169

- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 20 (6): 837-843

- **Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.** *Blood*
  Müller, A. M., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E., Florek, M., Zhang, P., Negrin, R. S., Shizuru, J. A.
  2014; 123 (18): 2882-2892

- **European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation** *BLOOD CANCER JOURNAL*
  Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., Miklos, D. B., Arai, S., Benjamin, J. E., Weng, W., Negrin, R. S., Lowsky, R.
  2014; 4

- **B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes.** *Clinical and experimental immunology*
  Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., Beilhack, G. F., Shizuru, J. A., Mellins, E. D.
  2013; 174 (1): 27-37

- **Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice** *IMMUNOGENETICS*
  Wang, Y., Chen, X., Tsai, S., Thomas, A., Shizuru, J. A., Cao, T. M.
  2013; 65 (8): 585-596

- **Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice** *IMMUNOGENETICS*
  Chen, X., Wang, Y., Li, Q., Tsai, S., Thomas, A., Shizuru, J. A., Cao, T. M.
  2013; 65 (8): 597-607

- **Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice** *ARTHRITIS AND RHEUMATISM*
  Rajasekaran, N., Wang, N., Phi Truong, P., Rinderknecht, C., Macaubas, C., Beilhack, G. F., Shizuru, J. A., Mellins, E. D.
  2013; 65 (3): 681-692

- **The road to purified hematopoietic stem cell transplants is paved with antibodies.** *Current opinion in immunology*
  Logan, A. C., Weissman, I. L., Shizuru, J. A.
  2012; 24 (5): 640-648

- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
  Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaenman, J., Brown, et al
  2012; 119 (25): 6145-6154

- **Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants** *AMERICAN JOURNAL OF TRANSPLANTATION*
  Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., Shizuru, J. A., Lowsky, R., Engleman, E. G., Strober, S.
  2012; 12 (5): 1133-1145

- **Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Mueller, A. M., Shashidhar, S., Kuepper, N. J., Kohrt, H. E., Florek, M., Negrin, R. S., Brown, J. M., Shizuru, J. A.
  2012; 109 (15): 5820-5825

- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
  Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
  2012; 47 (4): 581-588

- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*
  Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.
  2012; 47 (4): 516-521

- **Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Mueller, A. M., Kohrt, H. E., Cha, S., Laport, G., Klein, J., Guardino, A. E., Johnston, L. J., Stockerl-Goldstein, K. E., Hanania, E., Juttner, C., Blume, K. G., Negrin, R. S., Weissman, et al
  2012; 18 (1): 125-133

- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
  2011; 17 (11): 1679-1687

- **A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies** *BLOOD*
  Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Qiu, J., Cheng, E. C., McMillan, A., Johnston, L. J., Shizuru, J. A., Miklos, D. B.
  2011; 118 (15): 4070-4078

- **Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells** *JOURNAL OF IMMUNOLOGY*
  Linderman, J. A., Shizuru, J. A.
  2011; 186 (7): 4191-4199

- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
  Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
  2011; 46 (2): 192-199

- **Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.** *Proceedings of the National Academy of Sciences of the United States of America*
  Müller, A. M., Linderman, J. A., Florek, M., Miklos, D., Shizuru, J. A.
  2010; 107 (33): 14721-14726

- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
  2010; 16 (8): 1145-1154

- **Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*
  Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J., Sorror, M. L., Sahebi, F., McSweeney, P., Niederwieser, D., Bruno, B., Storb, R., Maloney, D. G.
  2010; 150 (2): 170-178

- **Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
  Gyurkocza, B., Storb, R., Storer, B. E., Chauncey, T. R., Lange, T., Shizuru, J. A., Langston, A. A., Pulsipher, M. A., Bredeson, C. N., Maziarz, R. T., Bruno, B., Petersen, F. B., Maris, et al
  2010; 28 (17): 2859-2867

- **Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure** *BONE MARROW TRANSPLANTATION*
  Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., Shizuru, J. A., JOHNSTON, L. J., Negrin, R. S., Lowsky, R., Laport, G. G.
  2010; 45 (2): 303-309

- **The biology of allogeneic hematopoietic cell resistance.** *Biology of blood and marrow transplantation*
  Shizuru, J. A., Bhattacharya, D., Cavazzana-Calvo, M.
  2010; 16 (1): S2-7

- **Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation** *JOURNAL OF IMMUNOLOGY*
  Filatenkov, A., Mueller, A. M., Tseng, W. W., Dejbakhsh-Jones, S., Winer, D., Luong, R., Shizuru, J. A., Engleman, E. G., Strober, S.
  2009; 183 (11): 7196-7203

- **Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
  Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., Franke, G. N., Sorror, M., Hoppe, R., Maloney, D. G., Negrin, R. S., Shizuru, J. A., Sandmaier, B. M.
  ELSEVIER SCIENCE INC.2009: 1314–22

- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
  Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
  2009; 114 (5): 1099-1109

- **A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice** *BLOOD*
  Cao, T. M., Thomas, A., Wang, Y., Tsai, S., Logronio, K., Shizuru, J. A.
  2009; 114 (1): 202-210

- **Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice** *JOURNAL OF IMMUNOLOGY*
  Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., Camp, N. J., Thomas, A., Shizuru, J. A.
  2009; 183 (1): 462-469

- **Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting** *BLOOD*
  Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., Maziarz, R. T., Chauncey, T. R., Appelbaum, et al
  2009; 113 (14): 3383-3391

- **Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Tsao, G. J., Allen, J. A., Logronio, K. A., Lazzeroni, L. C., Shizuru, J. A.
  2009; 106 (9): 3288-3293

- **The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases** *BLOOD*
  Weissman, I. L., Shizuru, J. A.
  2008; 112 (9): 3543-3553

- **Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience** *7th International Meeting on AAA Proteins*
  Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., Agura, E., Chauncey, T., Maziarz, R. T., Maris, M., Shizuru, J., Bruno, B., Bredeson, et al
  WILEY-BLACKWELL PUBLISHING, INC.2008: 395–403

- **Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning** *Tandem Bone Marrow Transplantation Meeting*
  Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., Maziarz, R., Agura, E., Chauncey, T. R., Pulsipher, M. A., McSweeney, P. A., Wade, J. C., Bruno, B., Langston, et al
  AMER SOC CLINICAL ONCOLOGY.2008: 4912–20

- **Complementing mutations in core binding factor leukemias: from mouse models to clinical applications** *ONCOGENE*
  Mueller, A., Duque, J., Shizuru, J. A., Luebbert, M.
  2008; 27 (44): 5759-5773

- **Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells** *HEPATOLOGY*
  Streetz, K. L., Doyonnas, R., Grimm, D., Jenkins, D. D., Fuess, S., Perryman, S., Lin, J., Trautwein, C., Shizuru, J., Blau, H., Sylvester, K. G., Kay, M. A.
  2008; 47 (2): 706-718

- **Tolerance and chimerism after renal and hematopoietic-cell transplantation.** *New England journal of medicine*

Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., Hoppe, R. T., Lowsky, R., Engleman, E. G., Strober, S.

2008; 358 (4): 362-368

- **Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma** *48th Annual Meeting of the American-Society-of-Hematology*

  Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., Wade, J. C., Chauncey, T., Forman, S. J., Lange, T., Shizuru, J., Langston, A., Pulsipher, et al

  AMER SOC CLINICAL ONCOLOGY.2008: 211–17

- **Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Georges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., Shizuru, J. A., Lange, T., Agura, E. D., Bruno, B., McSweeney, P. A., Pulsipher, M. A., Chauncey, T. R., Mielcarek, et al

  2007; 13 (4): 423-432

- **Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation** *47th Annual Meeting of the American-Society-of-Hematology*

  Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., Shizuru, J. A., Chauncey, T. R., Bruno, B., Forman, S. J., McSweeney, P. A., Maziarz, R. T., Pulsipher, M. A., Agura, et al

  AMER SOC CLINICAL ONCOLOGY.2006: 4150–57

- **Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

  Chaparro, R. J., Konigshofer, Y., Beilhack, G. F., Shizuru, J. A., McDevitt, H. O., Chien, Y.

  2006; 103 (33): 12475-12480

- **High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Shizuru, J. A., Blume, K. G., Negrin, R. S., Stockerl-Goldstein, K. E.

  2006; 12 (7): 703-711

- **Of mice and men** *BLOOD*

  Shizuru, J. A.

  2006; 107 (7): 2589-2590

- **Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Maris, M. B., Sandmaier, B. M., Storer, B. E., Maloney, D. G., Shizuru, J. A., Agura, E., Kliem, C., Pulsipher, M., Maziarz, R. T., McSweeney, P. A., Wade, J., Langston, A. A., Chauncey, et al

  2006; 12 (4): 454-465

- **Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

  Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., Holler, E., Ferrara, Y., Shulman, H., Lee, S. Y., Martin, P., Filipovich, A. H., Flowers, et al

  2006; 12 (2): 126-137

- **Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors** *JOURNAL OF CLINICAL ONCOLOGY*

  Hegenbart, U., Niederwieser, D., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., Greinix, H., Cordonnier, C., Rio, B., Gratwohl, A., Lange, T., Al-Ali, H., Storer, B., Maloney, et al

  2006; 24 (3): 444-453

- **Protective conditioning for acute graft-versus-host disease** *NEW ENGLAND JOURNAL OF MEDICINE*

  Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Hoppe, R. T., Bloch, D. A., Blume, K. G., Negrin, et al

  2005; 353 (13): 1321-1331

- **Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML** *LEUKEMIA*

  Kerbauy, F. R., STORB, R., Hegenbart, U., Gooley, T., Shizuru, J., Al-Ali, H. K., Radich, J. P., Maloney, D. G., Agura, E., Bruno, B., Epner, E. M., Chauncey, T. R., Blume, et al

  2005; 19 (6): 990-997

- **Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants** *DIABETES*
  Beilhack, G. F., Landa, R. R., Masek, M. A., Shizuru, J. A.
  2005; 54 (6): 1770-1779

- **Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation** *BRITISH JOURNAL OF HAEMATOLOGY*
  Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P. J., Sandmaier, B. M., Maloney, D. G., Maris, M. B., Chauncey, T. R., Shizuru, J. A., Blume, K. G., Hegenbart, U., Niederwieser, et al
  2005; 129 (3): 381-391

- **HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Stuart, M. J., McSweeney, P. A., Radich, J. P., Pulsipbek, M. A., Agura, E. D., Chauncey, T. R., Maloney, D. G., Shizuru, J. A., Storb, et al
  2005; 11 (4): 272-279

- **Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose** *BLOOD*
  Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Stuart, M. J., GRUMET, F. C., Negrin, R. S., Lowsky, R.
  2005; 105 (6): 2300-2306

- **CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies** *EXPERIMENTAL HEMATOLOGY*
  Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Negrin, R. S., Lowsky, R.
  2005; 33 (3): 279-285

- **Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., Negrin, R. S., Chao, N. J.
  2005; 11 (1): 47-55

- **Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system** *ANNUAL REVIEW OF MEDICINE*
  Shizuru, J. A., Negrin, R. S., Weissman, I. L.
  2005; 56: 509-538

- **Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Scheffold, C., Scheffold, J. C., Cao, T. M., Gworek, J., Shizuru, J. A.
  2005; 11 (1): 1-12

- **Genetic susceptibility loci for lethal graft-versus-host disease in MHC-identical mice: Initial results from a genome-wide scan.** *46th Annual Meeting of the American-Society-of-Hematology*
  Cao, T. M., Pang, W. W., Grumet, R. C., Lazzeroni, L. C., Shizuru, J. A.
  AMER SOC HEMATOLOGY.2004: 328B–328B

- **Approaches to transplantation tolerance in humans** *TRANSPLANTATION*
  Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., Millan, M. T.
  2004; 77 (6): 932-936

- **Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma** *43rd Annual Meeting of the American-Society-of-Hematology*
  Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Wong, R. M., Shizuru, J. A., Horning, S. J.
  AMER SOC HEMATOLOGY.2004: 777–83

- **Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Cao, T. M., Lo, B., Ranheim, E. A., GRUMET, F. C., Shizuru, J. A.
  2003; 100 (20): 11571-11576

- **Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation** *BLOOD*

Arber, C., Bitmansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., Weissman, I. L., Shizuru, J. A., Brown, J. M.
2003; 102 (2): 421-428

- **Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation** *BLOOD*
  Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., Parham, P.
  2003; 101 (9): 3730-3740

- **Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases** *BLOOD*
  Niederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., Sandmaier, B. M., Maloney, D. G., Storer, B., Lange, T., Chauncey, T., Deininger, M., Ponisch, W., Anasetti, et al
  2003; 101 (4): 1620-1629

- **Biology of hematopoietic stem cells and progenitors: Implications for clinical application** *ANNUAL REVIEW OF IMMUNOLOGY*
  Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. E., Shizuru, J. A., Weissman, I. L.
  2003; 21: 759-806

- **Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice** *DIABETES*
  Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., TAYLOR, C., Jerabek, L., Burge, M. J., Masek, M. A., Shizuru, J. A.
  2003; 52 (1): 59-68

- **Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant.** *44th Annual Meeting of the American-Society-of-Hematology*
  Little, M. T., Baker, J. E., Sandmaier, B. M., Maris, M. B., Maloney, D., Gooley, T., Oparin, D., Zellmer, E., Mielcarek, M., Wagner, J., Shizuru, J., Blume, K., Chauncey, et al
  AMER SOC HEMATOLOGY.2002: 39A–39A

- **Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion** *JOURNAL OF IMMUNOLOGY*
  Higuchi, M., Zeng, D. F., Shizuru, J., Gworek, J., Dejbakhsh-Jones, S., Taniguchi, M., Strober, S.
  2002; 169 (10): 5564-5570

- **Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases** *29th World Congress of the International-Society-of-Hematology*
  Georges, G. E., Maris, M., Sandmaier, B. M., Maloney, D. G., Feinstein, L., Niederweiser, D., Shizuru, J. A., McSweeney, P. A., Chauncey, T. R., Agura, E., Little, M. T., Sahebi, F., Hegenbart, et al
  SPRINGER JAPAN KK.2002: 184–189

- **Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation** *TRANSPLANTATION*
  Millan, T. L., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., Tan, J. C., Salvatierra, O., Hoppe, R. T., Strober, S.
  2002; 73 (9): 1386-1391

- **A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal**
  Millan, M. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., Tan, J. C., Salvatierra, O., Strober, S.
  FEDERATION AMER SOC EXP BIOL.2002: A1030–A1030

- **Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients** *BLOOD*
  Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., Blume, K. G., Stockerl-Goldstein, K. E., Levy, R., Shizuru, J. A.
  2002; 99 (4): 1442-1448

- **Non-myeloablative transplantation.** *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program*
  Maloney, D. G., Sandmaier, B. M., Mackinnon, S., Shizuru, J. A.
  2002: 392-421

- **Immunity to infections following hematopoietic cell transplantation** *CURRENT OPINION IN IMMUNOLOGY*
  Brown, J. M., Weissman, I. L., Shizuru, J. A.
  2001; 13 (4): 451-457

- **Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century** *FRONTIERS IN BIOSCIENCE-LANDMARK*
  Maris, M., Woolfrey, A., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D. G., Molina, A., Chauncey, T., Yu, C., Zaucha, J. M., Blume, K. G., Shizuru, et al
  2001; 6: G13-G16

- **Non-myeloablative hematopoietic stem cell transplantation** *ISBT 7th European Congress*
  Maris, M., Sandmaier, B. M., Maloney, D. G., McSweeney, P. A., Woolfrey, A., Chauncey, T., Shizuru, J., Niederwieser, D., Blume, K. G., Forman, S., Storb, R.
  ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER.2001: 231–34

- **Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects** *BLOOD*
  McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., Radich, J., Wagner, J. L., Minor, et al
  2001; 97 (11): 3390-3400

- **Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production** *BLOOD*
  Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., Negrin, R. S.
  2001; 97 (10): 2923-2931

- **Toward regenerative medicine** *IMMUNITY*
  Lagasse, E., Shizuru, J. A., Uchida, N., Tsukamoto, A., Weissman, I. L.
  2001; 14 (4): 425-436

- **Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., Shizuru, J. A.
  2001; 7 (10): 532-542

- **Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect** *3rd International Conference on Hematopoietic Stem Cells: Genetics and Medicine*
  Fenstein, L., SANDMAIER, B., Maloney, D., McSweeney, P. A., Maris, M., Flowers, C., Radich, J., Little, M. T., Nash, R. A., Chauncey, T., Woolfrey, A., Georges, G., Kiem, et al
  NEW YORK ACAD SCIENCES.2001: 328–339

- **Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., JOHNSTON, L. J., Shizuru, J. A., Long, G. D., Blume, K. G., Stockerl-Goldstein, K. E., Goldstein, S.
  2001; 7 (10): 552-560

- **High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., Shizuru, J. A., Hoppe, R. T., Brown, B. W., Blume, K. G., Stockerl-Goldstein, K.
  2001; 7 (5): 294-301

- **Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century** *6th Congress of the Asian-Society-of-Transplantation*
  Storb, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D. G., Molina, A., Chauncey, T., Yu, C., Zaucha, J. M., Blume, K. G., Shizuru, J., Niederwieser, et al
  ELSEVIER SCIENCE INC.2000: 2548–49

- **Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Shizuru, J. A., Weissman, I. L., Kernoff, R., Masek, M., Scheffold, Y. C.
  2000; 97 (17): 9555-9560

- **Effect of oral glutamine supplementation during bone marrow transplantation** *JOURNAL OF PARENTERAL AND ENTERAL NUTRITION*
  Dickson, T. M., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., Hu, W. W., Blume, K. G., Stockerl-Goldstein, K. E.
  2000; 24 (2): 61-66

- **Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., Wong, R. M., Chao, N. J., Long, G. D., Feiner, R. H., Blume, K. G.
  2000; 6 (1): 58-69

- **Non-myeloablative haematopoietic stem cell transplants** *4th International Stem Cell Workshop on High-Dose Therapy and Transplantation of Haematopoietic Stem Cells*
  STORB, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D., Yu, C., Zaucha, M., Blume, K., Shizuru, J., Niederwieser, D.
  BLACKWELL WISSENSCHAFTS-VERLAGGMBH.2000: 170–174

- **Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., Hu, W. W., JOHNSTON, L. J., Shizuru, J. A., Stockerl-Goldstein, K. E., Blume, K. G., Weissman, I. L., Bower, et al
  2000; 6 (3): 262-271

- **Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
  Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., Rizk, N. W., Wong, R. M., Blume, K. G., Hu, W. W.
  2000; 6 (4): 387-394

- **Immune reconstitution** *NEW ENGLAND JOURNAL OF MEDICINE*
  Weissman, I. L., Shizuru, J. A.
  1999; 341 (16): 1227-1229

- **Lymphoid development from stem cells and the common lymphocyte progenitors** *64th Symposia: Signaling and Gene Expression in the Immune System*
  Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., Domen, J., Mebius, R., Traver, D., Weissman, I. L.
  COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.1999: 1–12

- **Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.** *Biology of blood and marrow transplantation*
  Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., Shizuru, J. A., Johnston, L. L., Wong, R. M., Stockerl-Goldstein, K. E.
  1999; 5 (5): 299-305

- **Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.** *Biology of blood and marrow transplantation*
  Ito, M., Shizuru, J. A.
  1999; 5 (6): 357-368

- **From stem cells to lymphocytes: Biology and transplantation** *IMMUNOLOGICAL REVIEWS*
  Aguila, H. L., Akashi, K., Domen, J., Gandy, K. L., Lagasse, E., Mebius, R. E., Morrison, S. J., Shizuru, J., Strober, S., Uchida, N., Wright, D. E., Weissman, I. L.
  1997; 157: 13-40

- **Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.** *Biology of blood and marrow transplantation*
  Shizuru, J. A., Jerabek, L., Edwards, C. T., Weissman, I. L.
  1996; 2 (1): 3-14

- **VASCULAR ADDRESSINS ARE INDUCED ON ISLET VESSELS DURING INSULITIS IN NONOBESE DIABETIC MICE AND ARE INVOLVED IN LYMPHOID-CELL BINDING TO ISLET ENDOTHELIUM** *JOURNAL OF CLINICAL INVESTIGATION*
  Hanninen, A., TAYLOR, C., STREETER, P. R., Stark, L. S., SARTE, J. M., Shizuru, J. A., Simell, O., Michie, S. A.
  1993; 92 (5): 2509-2515

- **Anti-CD4 antibodies in diabetes.** *Immunology series*
  Shizuru, J. A., Fathman, C. G.
  1993; 59: 237-252

- **THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS** *TRANSPLANTATION*
  CHEN, R. H., IVENS, K. W., Alpert, S., Billingham, M. E., Fathman, C. G., Flavin, T. F., Shizuru, J. A., Starnes, V. A., Weissman, I. L., Griffiths, G. M.
  1993; 55 (1): 146-153

- **GENETIC-CONTROL OF DIABETES-MELLITUS** *3RD WORLD CONF ON DIABETES RESEARCH*
  Weatherall, D., Sarvetnick, N., Shizuru, J. A.
  SPRINGER VERLAG.1992: S1–S7

- **ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT** *IMMUNOLOGICAL REVIEWS*
  Shizuru, J. A., Alters, S. E., Fathman, C. G.
  1992; 129: 105-130

- **ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL** *DIABETES*
  SEYDEL, K., Shizuru, J., Grossman, D., Wu, A., Alters, S., Fathman, C. G.
  1991; 40 (11): 1430-1434

- **GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES** *JOURNAL OF EXPERIMENTAL MEDICINE*
  Shizuru, J. A., TAYLOREDWARDS, C., Livingstone, A., Fathman, C. G.
  1991; 174 (3): 633-638

- **TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS** *TRENDS IN ENDOCRINOLOGY AND METABOLISM*
  Shizuru, J. A., Sarvetnick, N.
  1991; 2 (3): 97-104

- **GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION** *JOURNAL OF IMMUNOLOGY*
  Livingstone, A., Edwards, C. T., Shizuru, J. A., Fathman, C. G.
  1991; 146 (2): 529-534

- **INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY** *TRANSPLANTATION*
  Shizuru, J. A., Seydel, K. B., Flavin, T. F., Wu, A. P., Kong, C. C., Hoyt, E. G., Fujimoto, N., Billingham, M. E., Starnes, V. A., Fathman, C. G.
  1990; 50 (3): 366-373

- **SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS** *9TH ANNUAL MEETING AND SCIENTIFIC SESSIONS OF THE INTERNATIONAL SOC FOR HEART TRANSPLANTATION*
  Flavin, T., Shizuru, J., SEYDEL, K., Wu, A., Fujimoto, N., Hoyt, E. G., Ivens, K., Billingham, M., Fathman, C. G., Starnes, V. A.
  MOSBY-YEAR BOOK INC.1990: 482–88

- **LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA** *NATURE*
  Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., Gregory, A., Parslow, T., Stewart, T.
  1990; 346 (6287): 844-847

- **THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T** *COLLOQUIUM ON DEFENSE MOLECULES*
  Danska, J. S., Livingstone, A. M., Shizuru, J., Fathman, C. G.
  WILEY-LISS, INC.1990: 241–254

- **CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY** *TRANSPLANTATION*
  TRAGER, D. K., Banks, B. A., Rosenbaum, G. E., HOLM, B. I., Shizuru, J. A., Strober, S., Fathman, C. G.
  1989; 47 (4): 587-591

- **INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE** *COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY*
  Sarvetnick, N., Shizuru, J., Liggitt, D., Stewart, T.
  1989; 54: 837-842

- **USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS** *TRANSPLANTATION*
  Kaufman, D. S., Kong, C. S., Shizuru, J. A., Gregory, A. K., Fathman, C. G.
  1988; 46 (2): 210-215

- **IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES** *SCIENCE*
  Shizuru, J. A., TAYLOREDWARDS, C., Banks, B. A., Gregory, A. K., Fathman, C. G.

1988; 240 (4852): 659-662

- **ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4** *SCIENCE*
  Shizuru, J. A., Gregory, A. K., CHAO, C. T., Fathman, C. G.
  1987; 237 (4812): 278-280
- **INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN** *TRANSPLANTATION*
  Shizuru, J. A., Ramakrishnan, S., Hunt, T., Merrell, R. C., Fathman, C. G.
  1986; 42 (6): 660-666
- **STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS** *DIABETES*
  Shizuru, J., Trager, D., Merrell, R. C.
  1985; 34 (9): 898-903